Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials
Current Language EN
English English Türkçe Türkçe Español Español Português Português Pусский Pусский Filipino Filipino Tiếng Việt Tiếng Việt हिन्दी हिन्दी العربية العربية বাংলা বাংলা Deutsch Deutsch 中文 中文

Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials

Crook, Derrick W.;Walker, A. Sarah;Kean, Yin;Weiss, Karl;Cornely, Oliver A.;Miller, Mark A.;Esposito, Roberto;Louie, Thomas J.;Stoesser, Nicole E.;Young, Bernadette C.;Angus, Brian J.;Gorbach, Sherwood L.;Peto, Timothy E. A.;for the Study 003/004 Teams;
clinical infectious diseases 2012 Vol. 55 pp. S93-S103
248
w.2012clinicalfidaxomicin

Abstract

Abstract. Two recently completed phase 3 trials (003 and 004) showed fidaxomicin to be noninferior to vancomycin for curing Clostridium difficile infection (CD

Keywords

Access

URL:
https://doi.org/10.1093/cid/cis499

Citation

ID: 113830
Ref Key: w.2012clinicalfidaxomicin
Use this key to autocite in SciMatic or Thesis Manager

References

References

No Bibliography

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
113830
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet
Gas fees required in SCI Coins
Buy SCI

Saymatik Web3.0 Wallet

Google Play
App Store